Correlated magnetic resonance imaging and ultramicroscopy (MR-UM) is a tool kit to assess the dynamics of glioma angiogenesis

Michael O Breckwoldt1,2,†, Julia Bode3,4,†, Felix T Kurz1, Angelika Hoffmann1, Katharina Ochs2,4, Martina Ott2,5, Katrin Deumelandt2,5, Thomas Krüwel6, Daniel Schwarz1, Manuel Fischer1, Xavier Helluy1,7, David Milford3, Klara Kirschbaum1, Gergely Solecki5, Sara Chiblak8,9,10, Amir Abdollahi8,9,10, Frank Winkler5, Wolfgang Wick5,11, Michael Platten2,5, Sabine Heiland1, Martin Bendszus†, Björn Tews3,4,†

1Neuroradiology Department, University Hospital Heidelberg, Heidelberg, Germany; 2Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany; 3Schaller Research Group, University of Heidelberg and German Cancer Research Center, Heidelberg, Germany; 4Molecular Mechanisms of Tumor Invasion, German Cancer Research Center, Heidelberg, Germany; 5Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; 6Department of Diagnostic and Interventional Radiology, University Medical Center Göttingen, Göttingen, Germany; 7Neuroimaging Centre, Research Department of Neuroscience, Ruhr-University Bochum, Bochum, Germany; 8German Cancer Consortium and Heidelberg Institute of Radiation Oncology, National Center for Radiation Research in Oncology, Heidelberg, Germany; 9Heidelberg University School of Medicine, Heidelberg University, Heidelberg, Germany; 10Translational Radiation Oncology, German Cancer Research Center, Heidelberg, Germany; 11Clinical Cooperation Unit Neurooncology, German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany

*For correspondence: michael.breckwoldt@med.uni-heidelberg.de (MOB); b.tews@dkfz-heidelberg.de (BT)
†These authors contributed equally to this work

Competing interests: The authors declare that no competing interests exist.

Funding: See page 15

Received: 18 September 2015
Accepted: 30 December 2015
Published: 02 February 2016

Reviewing editor: Ben Barres, Stanford School of Medicine, United States

Copyright Breckwoldt et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Abstract Neoangiogenesis is a pivotal therapeutic target in glioblastoma. Tumor monitoring requires imaging methods to assess treatment effects and disease progression. Until now mapping of the tumor vasculature has been difficult. We have developed a combined magnetic resonance and optical toolkit to study neoangiogenesis in glioma models. We use in vivo magnetic resonance imaging (MRI) and correlative ultramicroscopy (UM) of ex vivo cleared whole brains to track neovascularization. T2* imaging allows the identification of single vessels in glioma development and the quantification of neovessels over time. Pharmacological VEGF inhibition leads to partial vascular normalization with decreased vessel caliber, density, and permeability. To further resolve the tumor microvasculature, we performed correlated UM of fluorescently labeled microvessels in cleared brains. UM resolved typical features of neoangiogenesis and tumor cell invasion with a spatial resolution of ~5 µm. MR-UM can be used as a platform for three-dimensional mapping and high-resolution quantification of tumor angiogenesis.

DOI: 10.7554/eLife.11712.001
Introduction

Gliomas are highly malignant brain tumors with poor prognosis (Wen and Kesari, 2008). Glioblastoma multiforme (GBM) is characterized by high cellular proliferation rates and a rapid induction of angiogenesis (Wen and Kesari, 2008). Angiogenesis is a hallmark of malignant tumors, and most tumors show an exponential ingrowth of neovessels upon a certain tumor size to accommodate their metabolic needs (Carmeliet and Jain, 2011; Hanahan and Weinberg, 2011). This phenomenon is called the 'angiogenic switch' and is characterized by the upregulation of pro-angiogenic molecules like vascular endothelial growth factor (VEGF) or angiopoietin 2 (Ang-2) that induce fast tumor angiogenesis. The angiogenic switch is a central feature of malignant tumors and leads to a transition toward a more invasive and aggressive tumor growth (Bruno et al., 2014). Hence, many efforts have been made to develop antiangiogenic therapies to 'starve' tumors off their resources (Huang et al., 2003). So far, this approach of using anti-VEGF agents like bevacizumab has shown clinical benefit in certain tumor types (Mittal et al., 2014) but, despite significant improvement of progression-free survival, does not prolong overall survival of primary GBM in an unselected patient cohort (Chinot et al., 2014). Similarly, VEGF receptor 2 (VEGF-R2) inhibition, despite strong preclinical data (Batchelor et al., 2007; Winkler et al., 2004), has not been successful in neuro-oncology yet (Batchelor et al., 2013). New methods are currently developed to better identify those patients who might benefit from antiangiogenic therapies: Next to molecular approaches (Sandmann et al., 2015), magnetic resonance (MR) imaging could be used for patient stratification. In fact, accumulating data suggest that vascular normalization that occurs early after the initiation of therapy, might be such a marker which could aid clinical decision making (Emblem et al., 2013; Lu-Emerson et al., 2013).
However, improved imaging techniques that faithfully and non-invasively characterize vessel architecture and antiangiogenic treatment effects are needed to facilitate the understanding of biological actions of these therapies, and the development of clinical trials.

We employed a MR imaging approach to monitor tumor vessels at single vessel resolution. The technique is based on T2*-weighted (T2*-w) high-resolution Blood Oxygenation Level Dependent (BOLD) venography (Park et al., 2008) with standard gadolinium (Gd) contrast agents at ultrahigh-field strength (9.4 Tesla, isotropic 80 μm resolution). This visualizes substantially more vascular detail compared to conventional T2*-w imaging. We performed pre- and post-contrast MR scans to define angiogenesis during glioma development in two different glioma models. Also, we assess treatment effects of anti-VEGF or radiation therapy on the vascular compartment. We further mapped the tumor vascularization by correlated, dual-color ultramicroscopy (UM) of cleared, unsectioned brains (Ertürk et al., 2012; Schwarz et al., 2015). Fluorescent labeling of the microvasculature using lectins resulted in complementary 3D MR and UM data sets (dubbed ‘MR-UM’) of the entire tumor ‘macro-’ and ‘microvasculature’, which can be compared side-by-side. Thus, MR-UM bridges the gap between MR and optical imaging and may serve as a platform to better understand underlying mechanisms of antiangiogenic treatment and to identify novel druggable targets for preclinical therapy development.

Methods

Cell culture and glioma models

The mouse glioma cell line GL261 was purchased from National Cancer Institute (NCI Tumor Repository, Frederick, MD) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin (all from Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany). The 1x10⁵ GL261 cells diluted in 2-μl sterile phosphate buffered saline (PBS, Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) were stereotactically implanted into the right brain hemisphere of 6- to 8-week-old female C57Bl/6J mice (n=45 mice, Charles River Laboratories, Sulzfeld, Germany) using a Hamilton syringe, driven by a fine step motor (coordinates: 2 mm lateral and 2 mm ventral of bregma; injection depth: 3 mm below the dural surface). Animals were deeply anesthetized with ketamine/xylazine and unresponsive to stimuli during the intracranial injection; GL261 cells were routinely tested for viral or mycoplasma contamination, and mouse cell identity was confirmed by the multiplex cell contamination test (Multiplexion GmbH, Heidelberg, Germany, Schmitt and Pawlita, 2009). The human S24 cell line was derived as a primary glioblastoma culture from a resected glioblastoma (after informed consent) and GBM typical genetic changes were confirmed by comparative genomic hybridization (Lemke et al., 2012; Osswald et al., 2015). For the S24 glioma model, 5x10⁴ S24:td-tomato cells (stably transduced by lentivirus) were transplanted orthotopically in 8- to 10-week-old male NMRI nude mice (n=3 mice). The cells were cultivated under serum-free conditions in DMEM-F12 as sphere cultures (Thermo Fisher Scientific Inc., Waltham, MA) supplemented with 2% B-27 (Thermo Fisher Scientific Inc.), 5 μg/ml human insulin (Sigma-Aldrich Corporation, St. Louis, MO), 12.8 ng/ml heparin (Sigma-Aldrich Corporation), 0.4 ng/ml EGF (R&D Systems Inc., Minneapolis, MN) and 0.4 ng/ml FGF (Thermo Fisher Scientific Inc.). Cell lines were regularly checked for mycoplasma infections and authenticity (species control). Mycoplasma testing was done using the LookOut Mycoplasma PCR Detection Kit (Sigma-Aldrich, Germany) according to the manufacturer’s instructions. All animal experiments were approved by the regional animal welfare committee (permit number: G187/10, G188/12 and G145/10, Regierungspräsidium Karlsruhe).

MR imaging

MR imaging was performed on a 9.4 Tesla horizontal bore small animal NMR scanner (BioSpec 94/20 USR, Bruker BioSpin GmbH, Ettlingen, Germany) with a four-channel phased-array surface receiver coil. MR imaging included a standard RARE T2-w and T1-w post-Gd-contrast sequence to monitor tumor volume (T2-w parameters: 2D sequence, 78 μm in plane resolution, TE: 33 ms, TR: 2500 ms, flip angle: 90°, acquisition matrix: 200 x 150, number of averages: 2, slice thickness: 700 μm duration: 2 min 53 s; T1-w parameters: 2D sequence, 100 μm in plane resolution, TE: 6 ms, 1000 TR: ms, flip angle: 90°, acquisition matrix: 256 x 256, number of averages: 2, slice thickness: 500 μm,
duration: 5 min). To assess the tumor vasculature, we used a T2*-weighted gradient echo sequence (Park et al., 2008) and acquired pre- and post-contrast scans (3D sequence, 80 µm isotropic resolution, TE: 18 ms; TR: 50 ms; flip angle: 12°; number of averages: 1, acquisition matrix: 400 x 188 x 100, duration: 15 min 40 s). Pre-contrast images were used to differentiate susceptibility artifacts caused, for example, by tumor microbleedings from vessel signals that were only detectable after contrast administration. Dynamic contrast-enhanced (DCE) imaging (TE: 1.8 ms; TR: 16 ms; flip angle: 10°; slice thickness: 700 µm, acquisition matrix: 66 x 128, 3 slices acquired, number of averages: 1, 300 repetitions; 700 µm in plane resolution; duration: 10 min, time resolution 2 s) was used to assess vascular permeability ($K_{trans}$). 0.2 mmol/kg Gadodiamide (Omniscan, Nycomed, Ismaningen, Germany) was administered by tail vein injection for DCE and post-contrast scans. In five animals, 50 µl Gadodiamide was administered by intraperitoneal injection (ip), which had been determined before to match an iv dose of 0.2 mmol/kg. To assess the validity of the T2*-w sequence with an iron-based contrast agent, we performed blood pool imaging pre- and post-iv injections of crossed linked iron oxide nanoparticles (USPIO, CLIO-FITC, 15 mg/kg, particle size: 31 nm, kind gift by R. Weissleder, MGH, Boston). MR imaging was started 7 to 14 days post GL261 tumor cell implantation and repeated weekly up to 5 weeks after tumor cell implantation. For MR imaging, animals were anesthetized with 1–2% isoflurane. Animals were kept on a heating pad to keep the body temperature constant. Animal respiration was monitored externally during imaging with a breathing surface pad controlled by an in-house developed LabView program (National Instruments Corporation).

**Vascular permeability imaging**

DCE imaging was post-processed with OLEA software (OLEA Medical, La Ciotat, France). Pseudocolor images represent vascular permeability maps ($K_{trans}$) that were calculated using the Tofts and Kermode model (Tofts and Kermode, 1991). Quantification of DCE time series was performed in FIJI by ROI analysis of the main tumor slide and encompassing the entire tumor area. A mirror ROI was set in the contralateral hemisphere. Intensity values were measured and processed in Microsoft Excel (Microsoft). Signal ratios (SR) were calculated over time (SR = signal tumor / signal contralateral site) and displayed as blood–brain barrier disruption (BBB-D, arbitrary units, a.u.).

**Antiangiogenic therapy**

GL261 glioma-bearing mice were treated with the murine-chimeric anti-VEGF antibody which is based on the humanized anti-VEGF antibody B20-4.1 (Srivastava et al., 2014) or murine IgG control antibody (Roche, pRED Innovation Center Penzberg) at a dose of 10 mg/kg every 3 days by ip injection (four mice per group). Treatment was initiated 2 weeks after tumor cell implantation when a solid tumor was present on MRI. Animals were treated for 1 week (days 0, 3, 6) and MRI was performed on day 7 (3 weeks post inoculation) to quantify vascularization parameters. After the MR investigation, animals were injected with lectin-FITC or lectin-texas red and sacrificed for UM correlation.

**Radiotherapy**

Photon irradiation was delivered by XRAD320 X-ray device (Precision X-Ray, CT, USA). Animals were anesthetized by ketamine/xylazine during the procedure. Whole-brain irradiation was performed with a lateral photon beam at a dose of 2 grays per day. Irradiations were performed for four consecutive days starting 2 weeks after GL261 tumor implantation. The body was protected by lead shield to avoid radiation exposure to organs other than the brain. MR measurements were performed before (week 2) and after the completion of irradiation (week 3). Mice without irradiation served as controls (n=3 mice per group).

**Computed tomography**

To quantify the apparent volume loss of brain tissue induced by the clearing procedure, we performed computed tomography (CT) scans before and after clearing. Two 360° scans were obtained on a small animal CT (Quantum FX, Perkin Elmer, Waltham, MA) using the following parameter: 90 kV, 200 µA, 24 mm field of view, 40 µm isotropic resolution. Image reconstruction was performed using a standard filtered backprojection algorithm implemented in the vendor’s software.
maximum brain dimensions were determined in transversal slices and compared before and after clearing. We found that the brain volumes shrinks by ~40% but that the ratio of maximum length/width stays constant before and after clearing (length and width pre clearing: 1.33 ± 0.54 cm x 1.05 ± 0.38 cm; post clearing: 0.79 ± 0.24 cm x 0.62 ± 0.17 cm; ratio: 1.25 ± 0.01 and 1.28 ± 0.03, p>0.05 for ratio comparison).

Image processing and analysis of MR data

The vascularized area was quantified in Osirix software (V.4.12, Pixmeo, Geneva) by manually selecting region of interests (ROIs) around tubular vessel-like structures on post-contrast T2*-w images. Care was taken to exclude areas that were hypointense on pre-contrast images and most likely represent microbleedings or calcifications. For histogram analysis, the tumor region and an outside region in the frontal white matter were manually segmented. Intensity values for histogram analysis were read out in Matlab (Release 2015a, The MathWorks, Inc., Natick, MA). Images were normalized using the following formula: (mean voxel intensity_{tumor} – intensity_{outside})/standard deviation (SD).

Labeling of the microvasculature and assessment of BBB-D

For correlative optical microscopy of the microvasculature, animals were injected with fluorescent lectins that bind to N-acetyl-β-D-glucosamine oligomers of endothelial cells (Wächli et al., 2015). Injection of isolectin-FITC (12 mg/kg, Sigma) or lectin-texas red from Lycopersicon esculentum (12 mg/kg; Vector laboratories) was performed via the tail vein in 100 μl PBS after MRI. Animals were sacrificed 5 min after lectin injection by a ketamine/xylazine overdose and transcardially perfused with 5 ml PBS followed by 10 ml 4% paraformaldehyde (Histofix, Carl Roth GmbH, Karlsruhe). For the assessment of BBB-D, animals (n=2) were iv injected with 150 μl of 2% Evans blue (EB, Sigma) diluted in PBS. Animals were sacrificed 10 min after EB injection and cleared using the FluoClear-BABB protocol (see below). Caution must be taken when using EB in UM as prolonged animal perfusion and clearing can result in a drop of fluorescent signal due to a possible washout of the hydrophilic compound.

Fixation and clearing of mouse brains

Brains were fixed after perfusion with 4 % buffered formalin for at least 24 hr at 4°C in the dark. For UM-analysis, whole brains were optically cleared using organic solvents. Clearing was performed according to the 3DISCO protocol (Ertürk et al., 2011; 2012). Brains were transferred into glass vials for tetrahydrofuran (THF; Sigma Aldrich) dehydration. Two milliliter of 50 % THF were gently added using a pipette. Vials were placed into black 50-ml Falcon tubes and then mounted onto an overhead turning wheel (program C3, 15 rpm, Neolab, intelli-mixer). Clearing was performed at room temperature. After 12 hr, the 50 % THF solution was exchanged by a 70 % THF solution. Vials were again put into black Falcon tubes and mounted onto the turning wheel for another 12 hr. The procedure was repeated with 80% and 100 % THF solutions, respectively. Samples were incubated for 12 hr in 100 % THF for three times. The dehydrated brains were placed in benzyl ether for 48 hr in order to clear the samples (98 % dibenzyl ether, DBE, Sigma-Aldrich, Steinheim, Germany). To avoid degradation of the fluorescent signal, samples were kept in the dark and imaged immediately after the clearing procedure. S24 tumor-bearing brains were cleared with the recently published protocol FluoClearBABB (Schwarz et al., 2015). This protocol is based on benzyl alcohol/benzyl benzoate clearing in combination with a basic pH, which is maintained throughout the clearing procedure. The protocol is especially suited for effective clearing of aged mouse brains. Mice were perfused with lectin-FITC as described. After dissection, brains were kept in PBS at 4°C. For the dehydrogen of brains, analytical grade alcohol (t-butanol, Sigma) was diluted with double-distilled water. Brains were dehydrated using t-butanols ranging from 30 to 100 %. The clearing solution BABB was prepared by mixing benzyl alcohol (Merck, analytical grade) and benzyl benzoate (Sigma, ‘purissimum p.A.’ grade) in a 1: 2 volume ratio. The pH levels of dehydration and clearing solutions were adjusted using an InLab Science electrode suited for organic solvents (Mettler-Toledo). pH levels were adjusted with triethylamine (Sigma-Aldrich).
Acquisition of ultramicroscopy data sets
The cleared brains were scanned with a light sheet microscope (LaVision BioTec GmbH, Bielefeld, Germany). We used 0.63x, 1.0x, and 2.0x with a 2x objective lens and a white light laser (SuperK EXTREME 80 mHz VIS; NKT Photonics, Cologne, Germany) with a wavelength spectrum ranging from 400 to 2400 nm (pixel size for 0.63x: 5.16 μm; for 1.0x: 3.25 μm and for 2.0x: 1.62 μm). For the detection of blood vessels, the following filters were used: lectin-FITC, excitation 470 / 40 nm; emission 525 / 50 nm; lectin-texas red excitation 545 / 25; emission 585 / 40.

Z-stacks with 5 μm step size and a total range of up to 1500 to 2000 μm for the transversal measurement of the whole brain were acquired. Measurements with exposure times of 300 ms per slice resulted in a total acquisition time of ~10 min per brain sample and magnification. Images were exported as tagged image file (tif) and further post-processed in the ImageJ package FIJI, version 1.49 (http://fiji.sc/Fiji). For the generation of UM movies, the ‘Running Z projector’ plugin (FIJI) was used.

Quantification of ultramicroscopy data
Representative single slices from light sheet microscopy data sets were scaled in FIJI to a resolution of 0.5 x 0.5 μm². ROIs were manually chosen inside the tumor region and in a region not affected by tumor or vessel alterations (‘outside’). Vessels were identified with the FIJI plugin ‘tubeness’ that finds linear structures in an image (Sato et al., 1998). The resulting images were binarized individually to ensure maximal congruence with the respective vessels on the original image slice. For each binarized ROI, vessel objects were identified and skeletonized using Matlabs built-in functions ‘bwmorph’ and ‘regionprops’. After subtracting vessel branch points of the skeletonized image, the length of each vessel segment was determined. To obtain the vessel diameter and to avoid very small vessel cross-sections with minimal length, only those segments were considered whose lengths were longer than the difference of mean and standard error of the segment length distribution. For each pixel i of each segment S, the minimum distance to a non-vessel pixel was determined as the pixel-specific segment radius ri. Subsequently, we determined average segment radius \( r_S = \sum_{i \in S} r_i / \sum_{i \in S} \) and overall mean segment radius \( \bar{r} = \sum_S r_S / \sum_S \). The tortuosity of the longest 10% of the segments was obtained by dividing segment length by the Euclidean distance between its endpoints. The quantification of the vasculature in the 3D stack was performed in Amira (FEI, Hillsboro). The tumor and an ‘outside region’ were segmented in UM data sets (100–200 images per stack). Segmentation of the vasculature was performed semi-automatically based on pixel intensity. Thresholded images were median filtered, skeletonized and vessel length and radius were quantified.

Immunohistochemistry
To correlate MRI findings to histology 10 μm coronal cryostat sections were cut. Hematoxylin & eosin staining was performed for anatomical assessment. Lectin-FITC or lectin-texas red was injected iv in healthy animals (n=2) and dye labeling of endothelial cells was assessed on cryosections. Immunohistochemistry for endothelium (CD31 antibody, BD Bioscience) was performed using standard immunohistochemistry protocols and analyzed on a confocal laser-scanning microscope (Olympus FV1000). CD31 staining in lectin-FITC injected mice was performed in three GL261 tumor-bearing animals.

Statistical analysis
Data is shown as mean ± SEM. Statistical analyses were performed in PRISM (GraphPad). Two-tailed student’s t-tests were used to compare two groups. One-way ANOVA with Bonferroni’s post hoc testing was used for multiple comparisons. p-Values < 0.05 were considered significant. *denotes p<0.05; **p<0.01; ***p<0.001.
Results

Tumor vascularization can be monitored by contrast-enhanced T2*-weighted MRI

Glioma-bearing mice were monitored weekly with high-field MRI (9.4 T) starting 1 week after tumor cell implantation. Tumors could be clearly visualized by Gd-enhanced T1-weighted imaging (Figure 1a). Tumors grew rapidly and untreated mice got symptomatic and were sacrificed 4–5 weeks post implantation when they had developed large intracranial tumors (Figure 1a). To monitor vascularization both in the healthy brain and under pathological conditions, we employed a gradient echo, T2*-w sequence with high spatial resolution (80 μm isotropic resolution). This sequence allows the visualization of venules due to the BOLD effect of deoxygenized blood and the resulting susceptibility signals before contrast administration (Figure 1b). After administration of a clinically applied Gd-contrast agent, arterioles and venules show strong tubular vascular susceptibility signals that allow the assessment of the vascularization status (Figure 1b). Also, an iron-based experimental contrast agent (ultrasmall iron oxide nanoparticle, USPIO) resulted in a good delineation of the vasculature (Figure 1—figure supplement 1). In the healthy brain, for example, basal ganglia and cortical penetrating vessels can be visualized (Figure 1b and Figure 1—figure supplement 1). Under pathological conditions arterioles and venules within the tumor bed could be identified starting 2 weeks post-tumor implantation (Figure 1c, and Figure 1—figure supplement 2). First detectable vessels run both centrally and in the periphery of the developing glioma and could only be visualized after the administration of contrast material as tubular hypointense structures (Figure 1c).

Tumor vessel formation occurs within a short timespan

Within a week from the detection of first neovessels massive additional hypointense vessel-like structures occurred in the entire tumor bed as visualized on T2*-w images (Figure 1d and Videos 1,2). At this ‘late’ stage, single vessels were hard to differentiate within the tumor core because vascular density became too high for single vessel differentiation. Next to vascular susceptibility signals, also some dot-like susceptibility signals were found before contrast administration, most likely representing tumor microbleedings (Figure 1d). Kinetic studies showed that the Gd contrast agent is cleared from the circulation within ~2 hr after iv injection and vascular signals return to baseline within this time period (Figure 1—figure supplement 3). Quantification of the tumor size and vascularized area showed an exponential increase of tumor vessels over the time of investigation 1–3 weeks post-implantation (vascularized area week 1: 0.2 mm², week 2: 0.9 mm², week 3: 3.5 mm², p<0.01; Figure 1e,f). Histogram analysis of MR images showed a strong signal drop in the tumor area 3 weeks post-tumor cell implantation which was present only after contrast administration (Figure 1g,h). Interestingly, MRI was sensitive enough to detect single tumor vessels starting 2 weeks post implantation (Figure 1i). The resolution of MRI is, however, intrinsically limited to the μm range which is insufficient to resolve tumor vessels below ~50 μm in size. To validate and correlate our MR results to the cellular level, we performed UM in combination with tissue clearing.

Tumor vessel architecture can be visualized by light sheet microscopy

We adapted recently published light sheet microscopy protocols of cleared whole-brain specimen (Ertürk et al., 2012; Schwarz et al., 2015). Similar to MRI, UM results in 3D datasets but possess a ~10-fold higher resolution (Keller and Dodt, 2012). For UM, the microvasculature was assessed by lectin-FITC or lectin-texas red. These intravital dyes bind to endothelial glycoproteins in healthy tissue and tumor endothelium (Figure 2b and Figure 2—figure supplement 1, Wälchli et al., 2015). After MR imaging, animals were injected intravenously with lectin and sacrificed after 5 min of dye circulation. Subsequently, brains were explanted, cleared and vascularization was assessed by UM. The pathological neovascularization of the xenografted glioma was clearly visible: Single vessels in the tumor bed could be well delineated on correlated MRI and UM datasets (MR-UM) 2 weeks post-tumor implantation (Figure 2c and Videos 3, 4). Vessel density massively increased and large pathological vessels occurred 3 weeks post-tumor implantation (Figure 2d). In some larger tumors parts of the tumor core became necrotic and no vessels were present in these areas (Figure 2d). The MR-UM approach can also be employed for additional targets: for example, conventional Gd-enhanced
**Figure 1.** Imaging tumor vessel development with T2*-w sequences. Time course of tumor development on T1-w post Gd-contrast images (a). T2*-w images (80 μm resolution). Hypointense tubular structures, most likely venules (arrowheads), are visible due to the BOLD effect on pre-contrast images (upper row). Post-contrast administration arterioles and venules can be visualized (middle row). A minimum intensity projection (mIP) is shown in the bottom row (b). T2*-w images two and 3 weeks post-tumor implantation (c,d). Quantification of tumor sizes on T1-w post-contrast images (e). Quantification of the vascularized area on T2* images (f). Histogram analysis of the tumor region on post-contrast images 2 (green distribution) and 3 weeks (red) after tumor implantation. A significant signal drop (red distribution) within the tumor relative to the healthy white matter (WM) occurs within 1 week (p<0.001, g). This signal drop is only visible post-contrast administration (red distribution, p<0.001, h). Single plane T2*-w images pre- and post-contrast 2 weeks post-tumor implantation. The tubular vessel is only visible after contrast injection (i). Note the tortuous appearance and the multiple branches of the vessel. Scale bars are 1 mm.

DOI: 10.7554/eLife.11712.003

The following figure supplements are available for figure 1:

*Figure 1 continued on next page*
MRI can easily be correlated to optical Evans blue extravasation studies to assess BBB-D and vascular permeability within the tumor (R²: 0.87, p<0.001; Figure 2—figure supplement 2a–c).

### S24 tumors exhibit markedly different growth and angiogenesis patterns

The comparison of growth and angiogenesis patterns of primary, human S24 tumors with syngeneic mouse GL261 tumors by MR-UM revealed striking differences: S24 tumors grew markedly slower and highly invasive compared to GL261 tumors. Individual S24 tumor cell clusters were found outside of the tumor bulk even in the contralateral hemisphere. BBB-D, an early feature of GL261 tumors, developed in S24 tumors only at 10 weeks post-tumor implantation (Figure 2—figure supplement 3). At this time point, S24 tumors started to show clear signs of increased vascularity at the tumor stroma border on T2* post-contrast images and correlated UM (Figure 2e, Figure 2—figure supplement 3 and Video 5). UM also confirmed tumor cell infiltration into the contralateral hemisphere, which induced focal areas of aberrant vessel patterns with increased vessel density and diameter. The stable expression of red-fluorescent protein (td-tomato) by the S24 line allowed dual-color UM to assess the relation of cellular growth patterns and microvessel anatomy (Figure 2e).

### Tumor vessels show an increased diameter and density

For the quantification of UM data, vessels were segmented on single image planes and quantified using Matlab (Figure 3a). We found a progressive increase in vessel caliber 3 weeks post-tumor implantation compared to healthy regions (mean vessel diameter in outside regions: 3.2 μm; tumor region week 2: 11.5 μm, week 3: 14.7 μm; p<0.001, Figure 3b). Also, the tortuosity of tumor vessels was higher (tortuosity in outside regions: 1.11; tumor: 1.16; p=0.05; Figure 3c). Vessel density showed a trend toward higher densities within the tumor (0.16 vs. 0.11, n.s. Figure 3d). The assessment of vessel parameters in entire 3D data sets (100–200 images/animal) was performed with Amira software and showed likewise a significant increase of vessel radii and vessel pathlength within the tumor area compared to outside regions (Figure 3e–h). Large, CD31 positive microvessels with increased tortuosity were also confirmed within the tumor by immunohistochemistry (Figure 3—figure supplement 1a,b). In the tumor, however, some CD31-positive vessels were negative for lectin-FITC, indicating non-perfused vessels, whereas outside of the tumor all microvessels were double positive for CD31 and lectin-FITC (Figure 3—figure supplement 1c).
Figure 2. Correlated MR-UM provides complementary information of the tumor vascular architecture. Illustration of the mouse brain before and after clearing using the 3DISCO protocol. The brain shrinks by ~40% in size during the clearing protocol (a). Cleared UM images of lectin-FITC stained microvessels. Images show the healthy cortex (left) and hippocampus (middle). The glioma-stroma border (dotted line) is depicted on the right image (b). T2*-w images and correlative UM images 2 weeks, (c) and 3 weeks (d) after GL261 tumor implantation. Arrowheads indicate areas of necrosis. T2*-w image and correlative UM images 10 weeks after S24:td-tomato implantation. Inner necrotic tumor areas around the injection track lack fluorescent signal (e). The microvasculature is stained with lectin-FITC. MIP: maximum intensity projection, mIP: minimum intensity projection. Scale bar in (a) is 5 mm and 1 mm for MR images. For UM scale bars are 250 μm in (b) and 1 mm in (c-e).

DOI: 10.7554/eLife.11712.009

The following figure supplements are available for figure 2:

Figure supplement 1. Lectin-FITC and lectin-texas red staining in healthy mice.
DOI: 10.7554/eLife.11712.010

Figure supplement 2. Correlated permeability imaging using MR-UM.
DOI: 10.7554/eLife.11712.011

Figure supplement 3. Time course of S24 tumor development.
DOI: 10.7554/eLife.11712.012
Using correlated T2*-w and UM to quantify antiangiogenic treatment responses

To investigate the power of MR-UM for treatment monitoring, we inhibited the vascular endothelial growth factor with a murine antibody and monitored treatment effects on the vascular compartment. We found that neovessel-formation was partially blocked by VEGF inhibition (Figure 4a,b and Video 6). Also, the vascularized area and BBB-D decreased as assessed by T2*-w and DCE imaging (Figure 4c–f). UM quantification confirmed a partial block of pathological vessel features (vessel diameter and density) by VEGF inhibition (mean vessel diameter under VEGF treatment: 8.3 μm; isotype control: 13.2 μm; p<0.001; Figure 4g,h). The beneficial effect on the vascular compartment was specific for VEGF targeted therapy, as cytotoxic treatment with photon irradiation did not lead to signs of vascular normalization (Figure 4—figure supplement 1). Despite the efficient blockage of neoangiogenesis, anti-VEGF therapy did not lead to reduced tumor growth (tumor size 1 week after VEGF inhibition: 0.22 mm² vs 0.22 mm² in the isotype control group; p>0.05; four mice per group), reflecting current clinical data (Chinot et al., 2014; Taal et al., 2014).

Discussion

In this study, we combined in vivo 9.4 Tesla MRI with ex vivo UM and tissue clearing to dynamically resolve tumor arterioles and venules as well as the capillary bed of mouse gliomas at high resolution. Contrast-enhanced T2*-w imaging allowed the visualization of neovessels in the 50–100 μm range. In the GL261 model, angiogenesis started 2 weeks post-tumor implantation and massively increased until week 3. One limitation of MRI concerns its resolution, which was limited to ~80 μm in our study. To overcome this limitation, we employed correlated 3D UM of cleared specimen. For UM, we applied iv perfusion with fluorescent lectins that...
bind specifically to endothelial glycoproteins (Wälchli et al., 2015) and subsequent optical clearing of whole adult mouse brains using the well-established 3DISCO and the recently published FluoClearBABB protocol (Ertürk et al., 2012; Schwarz et al., 2015). We obtained high-quality images with both clearing methods that were used to reconstruct the entire tumor anatomy and blood vessel architecture including bulk mass and invasive zone. Tissue clearing and UM has not been employed for the study of neurooncological disease. Previous UM studies investigated microvessels under physiological conditions (Jährling et al., 2009) and in the context of solid visceral tumors...
Dobosz et al., 2014). We have extended this work to the field of neurooncology and combined it with advanced MRI techniques. This bridges the gap between MRI and whole brain optical microscopy, which represent separated domains so far. Optical clearing methods have recently undergone a rapid development and evoked large interest in the neuroscience community as they promise to...
allow 'connectomic' and circuit reconstruction studies (Chung et al., 2013; Dodt et al., 2007; Ertürk et al., 2011; Keller and Dodt, 2012; Schwarz et al., 2015; Susaki et al., 2014).

Clearing techniques are, however, also amenable to the study of pathological states: First reports have highlighted how 3D information obtained by tissue clearing can give new insights into pathophysiology of neuroinflammatory and neurodegenerative disease (Jährling et al., 2015; Spence et al., 2014).

The combination with MR, the most widely used clinical imaging technique, offers added value by correlating spatiotemporal information obtained by MR with high-resolution optical imaging. In the preclinical arena MR and UM with tissue clearing appear as natural partners as both produce 3D datasets, which can be compared side-by-side. The advantages of both techniques can be combined: Namely, MR is a versatile tool for longitudinal in vivo studies. UM of cleared specimen can resolve cellular and subcellular processes and utilize the vast toolbox of genetic and chemical fluorescent labels with their high molecular specificity, thus complementing the information gained by MRI. Also, a combination of the two techniques allows cross-correlation of in vivo signals with molecularly defined optical methods. To show the additive power of both methods, we used a neovascularization paradigm since neovessels are hallmarks of many diseases including cancer (Carmeliet and Jain, 2011; Goveia et al., 2014). Using cross-correlated MR-UM we achieved single vessel resolution and found pathological vessel permeability, tortuosity, and calibers, all of which could be partially reversed by VEGF treatment.

Our data indicate that similar to the human situation, mono-modality antiangiogenic treatment is not sufficient to halt glioma growth. Thus, novel antiangiogenic treatment regimes, possibly in combination with chemotherapy in recurrent disease (as done with promising results in the Dutch Belob Trial (Taal et al., 2014), and the ongoing EORTC 26,101 and 26,091 trials), or in combination with additional treatment modalities (i.e.immunotherapy, chemotherapy) are warranted (Chinot et al., 2014; Kamoun et al., 2009). Anti-angiogenic treatment development and clinical trials require imaging biomarkers to assess vascularization status and treatment effects. The developed T2*-w sequence is suitable to map tumor arterioles and venules in a preclinical setting. Future studies at high-field clinical MR systems should address a possible translation of our MRI approach to the clinical arena.

One limitation of our study relates to the differentiation of the various hierarchical parts of the vascular system. Tumors harbor a manifold of different vascular compartments (veins and arteries of different calibers and sizes with highly variable, but mostly pathological perfusion). Neither MR nor optical methods are able to capture the entire complexity of these compartments. Also, we found that in the bulk tumor some CD31 positive vessels were negative for lectin-FITC, indicating that some tumor vessels were hypo- or non-perfused. This implies that the visualization and quantification of the microvasculature by lectin-injection might slightly underestimate the vascular tumor compartment. The fact that hypo- or non-perfused vessels with abnormal flow exist in tumors is well established (Carmeliet and Jain, 2011). Another drawback might be that clearing methods may lead to an alteration in brain size, that is, due to dehydration. For 3DISCO, we quantified the apparent reduction of brain volume using CT imaging before and after clearing. This revealed a volume reduction of ~40%, which however occurred in a uniform fashion and did not change macroscopic tissue proportions. Anatomical structures and substructures of the brain remained fully intact. Vessel diameters obtained by UM could therefore be corrected by a multiplication factor of ~1.6. However, microscopic shrinkage may slightly differ from the macroscopic factor obtained by CT.

Also, when using endogenous fluorescent proteins such as GFP or RFP in combination with exogenous fluorescent markers such as FITC, preservation of fluorescent signals during the clearing process might vary and should be carefully controlled for.
In summary, the present study shows the additive power of correlative MR and UM for assessing the vascular system and the dynamic changes that occur in tumors over time. The applied principles should be easily transferable to additional targets like the immune cell compartment that are amenable to MR and optical labeling strategies (Kircher et al., 2003; Weissleder et al., 2014). Furthermore, MR-UM should be useful for translational approaches to aid preclinical therapy development. In our study, mono-antiangiogenic treatment with a murine VEGF inhibitor was insufficient to halt tumor growth which mirrors current human studies (Chinot et al., 2014). Dual angiogenesis inhibitors are currently being developed and therapeutic effects could be assessed in detail using our toolkit. Thus, we believe that MR-UM can provide a versatile platform for translational research approaches to cross-correlate MR and optical signals.

Acknowledgements

We are grateful for the kind gift of the murine VEGF inhibitor (Roche, pRED Innovation Center, Penzberg) and of USPIOs (Ralph Weissleder, Massachusetts General Hospital, Harvard Medical School). We thank Martin Schwab (University of Zurich) for critical discussion of the manuscript. We acknowledge support from the DKFZ Light Microscopy Core Facility. MOB, FTK and AH were supported by a physician-scientist fellowship of the Medical Faculty, University of Heidelberg. MOB and FTK are further supported by the Hoffmann-Klose Foundation (University of Heidelberg). MOB acknowledges funding by Neurowind e.V. This study was further supported by funds of the Chica and Heinz Schaller (CHS) Foundation (BT).

Additional information

Funding

| Funder                          | Author                  |
|---------------------------------|-------------------------|
| Medical Faculty, University of  | Michael O Breckwoldt    |
| Heidelberg                      | Felix T Kurz            |
|                                 | Angelika Hoffmann       |
| CHS Stiftung                    | Björn Tews              |
|                                 | Julia Bode              |

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions

MOB, JB, FTK, KO, TK, FW, MP, MB, BT, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article; AH, GS, Acquisition of data, Drafting or revising the article, Contributed unpublished essential data or reagents; MO, Conception and design, Acquisition of data, Analysis and interpretation of data; KD, KK, SC, AA, SH, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article; DS, Conception and design, Acquisition of data, Drafting or revising the article; MF, XH, DM, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished essential data or reagents; WW, Conception and design, Analysis and interpretation of data, Drafting or revising the article

Ethics

Animal experimentation: All animal experiments were approved by the regional animal welfare committee (permit number: G187/10, G188/12 and G145/10, Regierungspräsidium Karlsruhe).

References

Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, DeGroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jurgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M. 2013. Phase III randomized trial comparing the efficacy of cediranib as
monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. *Journal of Clinical Oncology* **31**:3212–3218. doi: 10.1200/JCO.2012.47.2464

Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen P-J, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Bennner T, Loeffler JS, Wen PY, Jain RK. 2007. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. *Cancer Cell* **11**:83–95. doi: 10.1016/j.ccc.2006.11.021

Bromberg A, Pagani A, Pulze L, Albini A, Dallaglio K, Noonan DM, Meller J. 2014. Orchestration of angiogenesis by immune cells. *Frontiers in Oncology* **4**:131. doi: 10.3389/fonc.2014.00131

Carmeliet P, Jain RK. 2011. Molecular mechanisms and clinical applications of angiogenesis. *Nature* **473**:298–307. doi: 10.1038/nature10144

Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpenter AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. 2014. Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. *New England Journal of Medicine* **370**:709–722. doi: 10.1056/NEJMoa1308345

Chung K, Wallace J, Kim SY, Kalyanasundaram S, Andalman AS, Davidson TJ, Mirzabekov JJ, Zalocusky KA, Mattis J, Denisin AK, Pak S, Bernstein H, Ramakrishnan C, Grosenick L, Gradinaru V, Deisseroth K. 2013. Structural and molecular interrogation of intact biological systems. *Nature* **497**:332–337. doi: 10.1038/nature12107

Doobz M, Ntziachristos V, Scheuer W, Strobel S. 2014. Multispectral fluorescence ultramicroscopy: three-dimensional visualization and automatic quantification of tumor morphology, drug penetration, and antiangiogenic treatment response. *Neoplasia* **16**:1–W7. doi: 10.1593/neo.131848

Dodd H-U, Leischner U, Schierloh A, Jährling N, Mauch CP, Deininger K, Deussing JM, Eder M, Ziegglänsberger W, Becker K. 2007. Ultramicroscopy: three-dimensional visualization of neuronal networks in the whole mouse brain. *Nature Methods* **4**:331–336. doi: 10.1038/nmeth0336

Emblem KE, Mouridsen K, Björnerud A, Farrar CT, Jennings D, Borra RJH, Wen PY, Ivy P, Batchelor TT, Rosen BR, Jain RK, Sorensen AG. 2013. Vessel architectural imaging identifies cancer patient responders to antiangiogenic therapy. *Nature Medicine* **19**:1178–1183. doi: 10.1038/nm.3289

Ertürk A, Becker K, Jährling N, Mauch CP, Hojer CD, Egen JG, Helfal F, Bradke F, Sheng M, Dodd H-U. 2012. Three-dimensional imaging of solvent-cleared organs using 3DISCO. *Nature Protocols* **7**:1983–1995. doi: 10.1038/nprot.2012.119

Ertürk A, Mauch CP, Hellal F, Förstner F, Keck T, Becker K, Jähring N, Steffens H, Richter M, Hübener M, Kramer E, Kirchhoff F, Dodd HU, Bradke F. 2011. Three-dimensional imaging of the unsectioned adult spinal cord to assess axon regeneration and glial responses after injury. *Nature Medicine* **18**:166–171. doi: 10.1038/ nm.2600

Geveela J, Stapor P, Carmeliet P. 2014. Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease. *EMBO Molecular Medicine* **6**:1105–1120. doi: 10.15252/emmm.201404156

Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. *Cell* **144**:646–674. doi: 10.1016/j.cell.2011.02.013

Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, O’Toole K, Zabski S, Rudge HS, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ. 2003. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. *Proceedings of the National Academy of Sciences of the United States of America* **100**:7785–7790. doi: 10.1073/pnas.1342908100

Jährling N, Becker K, Dodd H-U. 2009. 3D-reconstruction of blood vessels by ultramicroscopy. *Organogenesis* **5**:227–230. doi: 10.4161/org.5.4.10403

Jährling N, Becker K, Wegenast-Braun BM, Grathwohl SA, Jucker M, Dodd H-U, Vittorica J. 2015. Cerebral β-amyloidosis in mice investigated by ultramicroscopy. *PLOS One* **10**:e0125418. doi: 10.1371/journal.pone.0125418

Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munns LL, Fukumura D, Sorensen AG, Jain RK. 2009. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. *Journal of Clinical Oncology* **27**:2542–2552. doi: 10.1200/JCO.2008.19.9356

Keller PJ, Dodd H-U. 2012. Light sheet microscopy of living or cleared specimens. *Current Opinion in Neurobiology* **22**:138–143. doi: 10.1016/j.conb.2011.08.003

Kircher MF, Mahmoood U, King RS, Weissleder R, Josephson L. 2003. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. *Cancer Research* **63**:8122–8125.

Lemke D, Pfening P-N, Sahm F, Klein A-C, Kempf T, Warnken U, Schnolzer M, Tudorcan A, Chen H, Loffler JS, Ebendörfer K, Groenewold N, Klein A-C, Kempf T, Warnken U, Schnolzer M, Tudorcan A, Chen H, Loffler JS, Ebendörfer K, Groenewold N. 2012. Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. *Clinical Cancer Research* **18**:105–117. doi: 10.1158/1078-0432.CCR-11-0880

Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK. 2015. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. *Journal of Clinical Oncology* **33**:1197–1213. doi: 10.1200/JCO.2014.55.9575

Mittal K, Koon H, Elson P, Trezo P, Dowlati A, Chen H, Bordin EC, Rini BI. 2014. Dual VEGF/VEGFR inhibition in advanced solid malignancies. *Cancer Biology & Therapy* **15**:975–981. doi: 10.4161/cbt.29187

Osswald M, Jung E, Sahm F, Solecki G, Venkataramani V, Blaes J, Weil S, Horstmann H, Wistler B, Syed M, Huang L, Ratliff M, Karimian Jazi K, Kurz FT, Schmenger T, Lemke D, Gomml M, Paul M, Liao Y, Häring P,
Pusch S, Herl V, Steinhäuser C, Kronic D, Jarahian M, Miletic H, Berghoff AS, Griesbeck O, Kalamakis G, Garaschuk O, Preusser M, Weiss S, Liu H, Heiland S, Platten M, Huber PE, Kuner T, von Deimling A, Wick W, Winkler F.  2015. Brain tumour cells interconnect to a functional and resistant network. Nature 528:93–98. doi: 10.1038/nature16071

Park S-H, Masamoto K, Hendrich K, Kanno I, Kim S-G.  2008. Imaging brain vasculature with BOLD microscopy: MR detection limits determined by in vivo two-photon microscopy. Magnetic Resonance in Medicine 59:855–865. doi: 10.1002/mrm.21573

Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, Hegde P, Abrey LE, Phillips HS, Bais C.  2015. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. Journal of Clinical Oncology 33:2735–2744. doi: 10.1200/JCO.2015.61.5005

Sato Y, Nakajima S, Shiraga N, Atsumi H, Yoshida S, Koller T, Giger G, Kikinis R.  1998. Three-dimensional multiscale line filter for segmentation and visualization of curvilinear structures in medical images. Medical Image Analysis 2:143–168. doi: 10.1016/S1361-8415(98)80009-1

Schmitt M, Pawlita M.  2009. High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Research 37:e119. doi: 10.1093/nar/gkp581

Schwarz MK, Scherbarth A, Sprengel R, Engelhardt J, Theer P, Giese G, Merigan WH.  2015. Fluorescent-protein stabilization and high-resolution imaging of cleared, intact mouse brains. PLOS One 10:e0124650. doi: 10.1371/journal.pone.0124650

Spence RD, Kurfth F, Itoh N, Mongerson CRL, Wailes SH, Peng MS, MacKenzie-Graham AJ.  2014. Bringing CLARITY to gray matter atrophy. NeuroImage 101:625–632. doi: 10.1016/j.neuroimage.2014.07.017

Srivastava K, Hu J, Korn C, Savant S, Teichert M, Kapel SS, Jugold M, Besemfelder E, Thomas M, Pasparakis M, Augustin HG.  2014. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell 26:880–895. doi: 10.1016/j.cccell.2014.11.005

Susaki EA, Tainaka K, Perrin D, Kishino F, Tawara T, Watanabe TM, Yokoyama C, Onoe H, Eguchi M, Yamaguchi S, Abe T, Kiyonari H, Shimizu Y, Miyawaki A, Yokota H, Ueda HR.  2014. Whole-brain imaging with single-cell resolution using chemical cocktails and computational analysis. Cell 157:726–739. doi: 10.1016/j.cell.2014.03.042

Taal W, Oosterkamp HM, Walenkamp AME, Dubbink HJ, Beerepoot LV, Hanse MCJ, Buter J, Honkoop AH, Boerman D, de Vos FYF, Djinjens WNM, Enting RH, Taphoorn MJ, van den Berkmortel FWPJ, Jansen RLH, Brandsma D, Bromberg JEC, van Heuvel I, Vennhout RM, van der Holt B, van den Bent MJ.  2014. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The Lancet Oncology 15:943–953. doi: 10.1016/S1470-2045(14)70314-6

Tofts PS, Kermode AG.  1991. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. fundamental concepts. Magnetic Resonance in Medicine 17:357–367. doi: 10.1002/mmrm.1910170208

Wälchli T, Mateos JM, Weinman O, Babic D, Regli L, Hoerstrup SP, Gerhardt H, Schwab ME, Vogel J.  2015. Quantitative assessment of angiogenesis, perfused blood vessels and endothelial tip cells in the postnatal mouse brain. Nature Protocols 10:53–74. doi: 10.1038/nprot.2015.002

Weissleder R, Nahrendorf M, Pittet MJ.  2014. Imaging macrophages with nanoparticles. Nature Materials 13:125–138. doi: 10.1038/nmat3780

Wen PY, Kesari S.  2008. Malignant gliomas in adults. New England Journal of Medicine 359:492–507. doi: 10.1056/NEJMra0708126

Winkler F, Kozin SV, Tong RT, Chae S-S, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK.  2004. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation. Cancer Cell 6:553–563. doi: 10.1016/j.ccr.2004.10.011
Correlated magnetic resonance maging and ultramicroscopy (MR-UM) is a tool kit to assess the dynamics of glioma angiogenesis.